Ask AI

Medical Minutes

Share

Program Content

Activities

  • ALPINE Long Term Extension
    ALPINE Long-term Extension Study of Zanubrutinib in Relapsed or Refractory CLL/SLL
    Conference Coverage
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 24, 2026

    Expires: September 23, 2026

  • Bexobrutideg in RR CLL
    BTK Degrader Bexobrutideg in Patients With Relapsed/Refractory CLL/SLL  
    Conference Coverage
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 30, 2026

    Expires: September 29, 2026

  • CaDAnCe 101
    CaDAnCe-101 Phase I Study of the BTK Degrader BGB-16673 in R/R CLL/SLL  
    Conference Coverage
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 27, 2026

    Expires: September 26, 2026

  • BRUIN
    Final Analysis of the Phase I/II BRUIN Trial of Pirtobrutinib in Patients With CLL/SLL Previously Treated with a Covalent BTKi    
    Conference Coverage
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 26, 2026

    Expires: September 25, 2026

  • BRUIN CLL-314
    BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL  
    Conference Coverage
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 27, 2026

    Expires: September 26, 2026

  • Second Line Pirtobrutinib
    Second-line Pirtobrutinib in CLL/SLL After Covalent BTKi Treatment: A Pooled Analysis of BRUIN LOXO-BTK18001 and BRUIN CLL-321  
    Conference Coverage
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 30, 2026

    Expires: September 29, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Lilly.

Lilly